Horizon Pharma to Acquire Hyperion Therapeutics for $1.1 Billion

Palo Alto – March 31, 2015 – Cooley is advising Horizon Pharma plc on its agreement to acquire Hyperion Therapeutics for $1.1 billion in an all cash transaction and related debt commitments.

Horizon Pharma plc, which is headquartered in Dublin, Ireland, is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. Hyperion Therapeutics is a commercial-stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases.

Earlier this month, Cooley advised Horizon Pharma and Horizon Pharma Investments Limited on its Rule 144A offering of $400 million aggregate principal amount of exchangeable senior notes due 2022.

About Cooley LLP

Cooley's lawyers solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, often where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Barbara Borden Partner, San Diego
Michelle Lara Special Counsel, San Diego
Sean Clayton Partner, San Diego
Rama Padmanabhan Partner, San Diego
Michael Tollini Partner, Washington, DC
Natasha Leskovsek Of Counsel, Washington, DC
Wade Andrews Associate, San Diego
Jacqueline Grise Partner, Washington, DC
Tanisha A. James Partner, New York
Amanda Fant Associate, San Francisco
Ben Beerle Partner, San Francisco
Dani Nazemian Associate, San Diego
Todd Gluth Partner, San Diego
Nicole P. van de Leuv Special Counsel, San Diego
Matthew D. Silverman Associate, San Diego